Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B

Hepatology

Volumn 32, Issue 4 I, 2000, Pages 847-851

  Hadziyannis, Stephanos J ^a   Papatheodoridis, George V ^a   Dimou, Evangelini ^a   Laras, Andreas ^a   Papaioannou, Christos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOCHEMICAL MARKER; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ACUTE HEPATITIS; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HEPATITIS B; HUMAN; LABORATORY DIAGNOSIS; LONG TERM CARE; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; VIRUS GENE;

EID: 0033803799     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.17915     Document Type: Article

References (27)

1. Hepatitis B virus infection
2. Chronic hepatitis B
3. The major etiology of hepatocellular carcinoma
4. Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment
5. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
6. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
7. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients
8. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
9. The treatment of chronic viral hepatitis
10. Long-term alpha-interferon therapy in anti-HBe positive chronic hepatitis B increases significantly the frequency of sustained response
11. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
12. A one-year trial of lamivudine for chronic hepatitis B
13. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
14. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
15. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B
16. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
17. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B
18. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon
19. Efficacy of prolonged lamivudine therapy in HBV DNA/HBeAb positive previously non responder chronic hepatitis B
20. Three year lamivudine therapy in chronic HBV
21. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
22. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
23. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
24. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
25. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
26. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
27. Hepatitis B virus reactivation after lamivudine discontinuation